[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Decompensated cirrhosis (MELD-Na 29) with vasodilatory shock refractory to norepinephrine (0.24 mcg/kg/min) and vasopressin (0.03 units/min), MAP 62 mm Hg, hyperdynamic LV, underfilled LV, collapsible IVC, CVP 4 mm Hg, ScvO2 76%, elevated lactate (5.1 mmol/L), and CRRT for azotemia/hyperkalemia—indicating catecholamine-resistant vasodilatory shock with RAAS dysregulation typical in advanced cirrhosis. These support adding angiotensin II (C) as a third-line agent targeting RAAS, while maintaining current MAP to avoid over-vasoconstriction. Main logical issue(s): None; stem provides sufficient discriminating details (e.g., hyperdynamic state rules out inotropes, adequate ScvO2 negates dobutamine need, ischemia risks with high vasopressin, splanchnic concerns with phenylephrine) to identify C as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., SCCM for refractory shock) and emerging evidence for angiotensin II in cirrhotic vasodilatory failure, accurately reflecting pathophysiology without outdated elements. Minimal fix: No edit needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Decompensated cirrhosis (MELD-Na 29) with vasodilatory shock refractory to norepinephrine (0.24 mcg/kg/min) and vasopressin (0.03 units/min), MAP 62 mm Hg, hyperdynamic LV, underfilled LV, collapsible IVC, CVP 4 mm Hg, ScvO2 76%, elevated lactate (5.1 mmol/L), and CRRT for azotemia/hyperkalemia—indicating catecholamine-resistant vasodilatory shock with RAAS dysregulation typical in advanced cirrhosis. These support adding angiotensin II (C) as a third-line agent targeting RAAS, while maintaining current MAP to avoid over-vasoconstriction. Main logical issue(s): None; stem provides sufficient discriminating details (e.g., hyperdynamic state rules out inotropes, adequate ScvO2 negates dobutamine need, ischemia risks with high vasopressin, splanchnic concerns with phenylephrine) to identify C as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., SCCM for refractory shock) and emerging evidence for angiotensin II in cirrhotic vasodilatory failure, accurately reflecting pathophysiology without outdated elements. Minimal fix: No edit needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Progressive symptoms (fatigue, weight loss, early satiety, night sweats), marked splenomegaly, cytopenias (anemia, thrombocytopenia), leukoerythroblastosis with teardrop cells and nucleated RBCs, elevated LDH/uric acid, dry tap with grade 3 fibrosis and atypical megakaryocytes, new complex karyotype with monosomy 7—all indicating high-risk post-PV myelofibrosis transformation. These high-risk features (constitutional symptoms, extramedullary hematopoiesis, adverse cytogenetics) prioritize curative intent via allogeneic HSCT evaluation over symptomatic or non-curative options. Main logical issue(s), if any: None; stem provides sufficient discriminating details to identify HSCT evaluation as the single best disease-directed step without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., NCCN for myelofibrosis) recommending HSCT evaluation for transplant-eligible patients with high-risk features like monosomy 7, while ruxolitinib is for symptom control but not curative; azacitidine is investigational/not first-line for MF; interferon and hydroxyurea escalation are inadequate for advanced disease. Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Progressive symptoms (fatigue, weight loss, early satiety, night sweats), marked splenomegaly, cytopenias (anemia, thrombocytopenia), leukoerythroblastosis with teardrop cells and nucleated RBCs, elevated LDH/uric acid, dry tap with grade 3 fibrosis and atypical megakaryocytes, new complex karyotype with monosomy 7—all indicating high-risk post-PV myelofibrosis transformation. These high-risk features (constitutional symptoms, extramedullary hematopoiesis, adverse cytogenetics) prioritize curative intent via allogeneic HSCT evaluation over symptomatic or non-curative options. Main logical issue(s), if any: None; stem provides sufficient discriminating details to identify HSCT evaluation as the single best disease-directed step without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., NCCN for myelofibrosis) recommending HSCT evaluation for transplant-eligible patients with high-risk features like monosomy 7, while ruxolitinib is for symptom control but not curative; azacitidine is investigational/not first-line for MF; interferon and hydroxyurea escalation are inadequate for advanced disease. Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute dyspnea, pleuritic pain, near syncope, hypotension (BP 82/48), tachycardia (HR 132), hypoxia (SpO2 89%), and echo findings of dilated RV with McConnell sign and septal flattening, indicating high-risk PE with RV strain; no thrombolysis contraindications, stable fetal status, CTA unavailable, duplex pending. These support immediate reperfusion for massive PE in pregnancy, prioritizing maternal survival. Main logical issue(s): none; stem is coherent, allows discrimination among options without contradictions or underspecification, as clues clearly favor systemic thrombolysis over alternatives. Main medical accuracy issue(s): none; aligns with ACCP/ESC guidelines for high-risk PE management in pregnancy, where systemic thrombolysis (e.g., alteplase) is recommended despite relative contraindication of pregnancy, with maternal benefit outweighing fetal risks; alternatives like catheter-directed or surgery are for failures/contraindications, deferral is unsafe, and tenecteplase lacks pregnancy-specific data. Minimal fix: none needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute dyspnea, pleuritic pain, near syncope, hypotension (BP 82/48), tachycardia (HR 132), hypoxia (SpO2 89%), and echo findings of dilated RV with McConnell sign and septal flattening, indicating high-risk PE with RV strain; no thrombolysis contraindications, stable fetal status, CTA unavailable, duplex pending. These support immediate reperfusion for massive PE in pregnancy, prioritizing maternal survival. Main logical issue(s): none; stem is coherent, allows discrimination among options without contradictions or underspecification, as clues clearly favor systemic thrombolysis over alternatives. Main medical accuracy issue(s): none; aligns with ACCP/ESC guidelines for high-risk PE management in pregnancy, where systemic thrombolysis (e.g., alteplase) is recommended despite relative contraindication of pregnancy, with maternal benefit outweighing fetal risks; alternatives like catheter-directed or surgery are for failures/contraindications, deferral is unsafe, and tenecteplase lacks pregnancy-specific data. Minimal fix: none needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-viral onset, symmetric flaccid weakness (legs > arms) with areflexia and intact sensation, normal MRI, mildly elevated CSF protein with low WBC, and NCS showing reduced CMAP amplitudes, preserved conduction velocities/distal latencies, normal sensory studies, and absent F-waves—pointing to a pure motor axonal neuropathy. These discriminate against demyelinating (AIDP: slowed velocities/prolonged latencies), sensory-involved (AMSAN), cranial/ataxic (Miller Fisher), or myelitic (AFM: MRI changes, asymmetry) options. Main logical issue(s): None; the vignette provides sufficient details for a single defensible best answer without contradictions or underspecification, as NCS findings uniquely support AMAN over alternatives. Main medical accuracy issue(s): None; aligns with current GBS variant classifications (e.g., AMAN as axonal motor subtype post-infection, often Campylobacter-linked but viral possible in children), with implications for potentially faster recovery with IVIG/plasmapheresis per guidelines. Minimal fix: None required; item is already unambiguous and accurate, though adding explicit infectious trigger (e.g., Campylobacter) could enhance realism without changing the key.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-viral onset, symmetric flaccid weakness (legs > arms) with areflexia and intact sensation, normal MRI, mildly elevated CSF protein with low WBC, and NCS showing reduced CMAP amplitudes, preserved conduction velocities/distal latencies, normal sensory studies, and absent F-waves—pointing to a pure motor axonal neuropathy. These discriminate against demyelinating (AIDP: slowed velocities/prolonged latencies), sensory-involved (AMSAN), cranial/ataxic (Miller Fisher), or myelitic (AFM: MRI changes, asymmetry) options. Main logical issue(s): None; the vignette provides sufficient details for a single defensible best answer without contradictions or underspecification, as NCS findings uniquely support AMAN over alternatives. Main medical accuracy issue(s): None; aligns with current GBS variant classifications (e.g., AMAN as axonal motor subtype post-infection, often Campylobacter-linked but viral possible in children), with implications for potentially faster recovery with IVIG/plasmapheresis per guidelines. Minimal fix: None required; item is already unambiguous and accurate, though adding explicit infectious trigger (e.g., Campylobacter) could enhance realism without changing the key.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 47-year-old with poorly controlled type 2 diabetes and alcohol use (immunocompromised), 10 days fever, right headache, confusion, disoriented, febrile, left hemiparesis, papilledema; CT shows 3.5-cm ring-enhancing right frontal lobe lesion with edema contiguous with opacified frontal sinus, after failed oral antibiotics for presumed sinusitis. These indicate brain abscess from sinus extension with mass effect, necessitating prompt surgical intervention addressing both abscess and source. Main logical issue(s): None; stem provides sufficient details for discriminating B as uniquely best—open craniotomy for abscess excision and sinus drainage eradicates infection source and relieves mass effect. Alternatives inferior: A (aspiration) risks re-seeding from untreated sinus; C addresses only sinus, not abscess; D manages potential hydrocephalus but not primary pathology; E delays surgery, risking herniation. Main medical accuracy issue(s): None; aligns with guidelines for large brain abscesses with sinus origin in immunocompromised patients—surgical excision plus source control is standard, especially with neurological deficits and mass effect; medical therapy alone insufficient. Minimal fix: Not needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 47-year-old with poorly controlled type 2 diabetes and alcohol use (immunocompromised), 10 days fever, right headache, confusion, disoriented, febrile, left hemiparesis, papilledema; CT shows 3.5-cm ring-enhancing right frontal lobe lesion with edema contiguous with opacified frontal sinus, after failed oral antibiotics for presumed sinusitis. These indicate brain abscess from sinus extension with mass effect, necessitating prompt surgical intervention addressing both abscess and source. Main logical issue(s): None; stem provides sufficient details for discriminating B as uniquely best—open craniotomy for abscess excision and sinus drainage eradicates infection source and relieves mass effect. Alternatives inferior: A (aspiration) risks re-seeding from untreated sinus; C addresses only sinus, not abscess; D manages potential hydrocephalus but not primary pathology; E delays surgery, risking herniation. Main medical accuracy issue(s): None; aligns with guidelines for large brain abscesses with sinus origin in immunocompromised patients—surgical excision plus source control is standard, especially with neurological deficits and mass effect; medical therapy alone insufficient. Minimal fix: Not needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 66-year-old with COPD and metastatic NSCLC on pembrolizumab, presenting with worsening exertional dyspnea, dry cough, O2 saturation 90% on room air (acceptable for COPD target 88-92%, no supplemental O2 indicated), new bilateral patchy ground-glass opacities and reticular changes with subpleural sparing, exclusion of infection/PE/cardiac causes. These point to grade 2 immune-related pneumonitis (symptomatic, radiographic changes, no O2 requirement or life-threatening features), managed by holding pembrolizumab and starting prednisone 1-2 mg/kg/day. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, as COPD context clarifies O2 sat does not trigger grade 3. Main medical accuracy issue(s), if any: None; aligns with CTCAE grading, ASCO/NCCN guidelines for ICI pneumonitis (grade 2: hold ICI, oral steroids 1-2 mg/kg; grade 3 requires O2/severe symptoms, IV steroids, potential permanent discontinuation; infliximab for refractory cases). Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 66-year-old with COPD and metastatic NSCLC on pembrolizumab, presenting with worsening exertional dyspnea, dry cough, O2 saturation 90% on room air (acceptable for COPD target 88-92%, no supplemental O2 indicated), new bilateral patchy ground-glass opacities and reticular changes with subpleural sparing, exclusion of infection/PE/cardiac causes. These point to grade 2 immune-related pneumonitis (symptomatic, radiographic changes, no O2 requirement or life-threatening features), managed by holding pembrolizumab and starting prednisone 1-2 mg/kg/day. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, as COPD context clarifies O2 sat does not trigger grade 3. Main medical accuracy issue(s), if any: None; aligns with CTCAE grading, ASCO/NCCN guidelines for ICI pneumonitis (grade 2: hold ICI, oral steroids 1-2 mg/kg; grade 3 requires O2/severe symptoms, IV steroids, potential permanent discontinuation; infliximab for refractory cases). Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 9-year-old with non-metastatic WNT-activated medulloblastoma (CTNNB1 mutation, monosomy 6), near-total resection, histology with Homer-Wright rosettes, implying standard-risk category per current classifications. These support reduced-dose craniospinal irradiation (CSI) with posterior fossa boost plus chemotherapy to balance efficacy and toxicity reduction. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best choice. Main medical accuracy issue(s), if any: None; aligns with COG/ACNS0331 protocols for standard-risk medulloblastoma (age >3, M0, residual <1.5 cm²), where WNT subtype has >90% survival with de-escalated therapy; avoids overtreatment (A) or undertreatment (B, D, E). Minimal fix: None needed.\\n\\nBest-answer defensibility: a) Question asks for most appropriate adjuvant therapy in pediatric WNT medulloblastoma post-resection. b) Key findings: Age 9, progressive symptoms, posterior fossa mass, WNT-activated, non-metastatic, near-total resection. c) Most likely: Standard-risk management. d) C fits as per guidelines, assuming near-total means minimal residual. e) A: Overkill for non-high-risk; B: Misses CSI need; D: Risks recurrence; E: Not standard.\\n\\nLogical validity: V; unique best answer matches key. Medical accuracy: Consistent with NCCN/COG standards; no inaccuracies.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 9-year-old with non-metastatic WNT-activated medulloblastoma (CTNNB1 mutation, monosomy 6), near-total resection, histology with Homer-Wright rosettes, implying standard-risk category per current classifications. These support reduced-dose craniospinal irradiation (CSI) with posterior fossa boost plus chemotherapy to balance efficacy and toxicity reduction. Main logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best choice. Main medical accuracy issue(s), if any: None; aligns with COG/ACNS0331 protocols for standard-risk medulloblastoma (age >3, M0, residual <1.5 cm²), where WNT subtype has >90% survival with de-escalated therapy; avoids overtreatment (A) or undertreatment (B, D, E). Minimal fix: None needed.\n\nBest-answer defensibility: a) Question asks for most appropriate adjuvant therapy in pediatric WNT medulloblastoma post-resection. b) Key findings: Age 9, progressive symptoms, posterior fossa mass, WNT-activated, non-metastatic, near-total resection. c) Most likely: Standard-risk management. d) C fits as per guidelines, assuming near-total means minimal residual. e) A: Overkill for non-high-risk; B: Misses CSI need; D: Risks recurrence; E: Not standard.\n\nLogical validity: V; unique best answer matches key. Medical accuracy: Consistent with NCCN/COG standards; no inaccuracies.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Sudden aphasia/hemiplegia 70 min ago, left M1 occlusion on CTA, no hemorrhage on CT, recent rivaroxaban (3 hours prior) with elevated anti-Xa (170 ng/mL), normal Cr/platelets/INR, center with MT capability and reversal agents available. These indicate acute ischemic stroke with LVO in patient on DOAC, where IV tPA is contraindicated due to recent ingestion and high anti-Xa, making direct MT the best strategy without thrombolysis or reversal attempts for tPA.\\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating C as uniquely best, with no contradictions or underspecification—options are comparable, and only C aligns without requiring unstated assumptions.\\nMain medical accuracy issue(s), if any: None; aligns with AHA/ASA guidelines: DOAC use with elevated anti-Xa contraindicates IV tPA; reversal (andexanet/PCC) before tPA lacks evidence and is not recommended; direct MT is preferred for eligible LVO patients on anticoagulants.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Sudden aphasia/hemiplegia 70 min ago, left M1 occlusion on CTA, no hemorrhage on CT, recent rivaroxaban (3 hours prior) with elevated anti-Xa (170 ng/mL), normal Cr/platelets/INR, center with MT capability and reversal agents available. These indicate acute ischemic stroke with LVO in patient on DOAC, where IV tPA is contraindicated due to recent ingestion and high anti-Xa, making direct MT the best strategy without thrombolysis or reversal attempts for tPA.\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating C as uniquely best, with no contradictions or underspecification—options are comparable, and only C aligns without requiring unstated assumptions.\nMain medical accuracy issue(s), if any: None; aligns with AHA/ASA guidelines: DOAC use with elevated anti-Xa contraindicates IV tPA; reversal (andexanet/PCC) before tPA lacks evidence and is not recommended; direct MT is preferred for eligible LVO patients on anticoagulants.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 22-year-old with HbSS sickle cell disease presents with fever, cough, pleuritic pain, multilobar infiltrates on CXR, hypoxemia (SpO2 93% on 2L NC), anemia (Hgb 7.2 vs baseline 8.5), leukocytosis (WBC 18k), high reticulocytes (12%); diagnosed ACS, treated with antibiotics, spirometry, simple transfusion to Hgb 9.5; worsens over 24h with increased O2 need (8L, SpO2 90%), radiographic progression to bilateral opacification, Hgb now 10.3, tachypnea without intubation. These indicate severe, progressive ACS unresponsive to initial management, pointing to need for escalation to exchange transfusion to reduce HbS <30%.\\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with ASH and NHLBI guidelines for severe ACS in SCD, where exchange transfusion is preferred over further simple transfusion to avoid viscosity risks; alternatives appropriately inferior (A risks hyperviscosity, C controversial with rebound risks, D lacks PE evidence, E supportive but not disease-modifying).\\nMinimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 22-year-old with HbSS sickle cell disease presents with fever, cough, pleuritic pain, multilobar infiltrates on CXR, hypoxemia (SpO2 93% on 2L NC), anemia (Hgb 7.2 vs baseline 8.5), leukocytosis (WBC 18k), high reticulocytes (12%); diagnosed ACS, treated with antibiotics, spirometry, simple transfusion to Hgb 9.5; worsens over 24h with increased O2 need (8L, SpO2 90%), radiographic progression to bilateral opacification, Hgb now 10.3, tachypnea without intubation. These indicate severe, progressive ACS unresponsive to initial management, pointing to need for escalation to exchange transfusion to reduce HbS <30%.\nMain logical issue(s), if any: None; stem provides sufficient details for discriminating a single best next step without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with ASH and NHLBI guidelines for severe ACS in SCD, where exchange transfusion is preferred over further simple transfusion to avoid viscosity risks; alternatives appropriately inferior (A risks hyperviscosity, C controversial with rebound risks, D lacks PE evidence, E supportive but not disease-modifying).\nMinimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include cirrhosis with portal hypertension, hyperammonemia (96 µmol/L), supratherapeutic free valproate despite therapeutic total level, low carnitine, EEG showing triphasic waves without epileptiform activity, and presentation of confusion/seizures suggestive of metabolic encephalopathy rather than primary epilepsy. These point to valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency, making discontinuation of valproate essential, with switch to levetiracetam (renally cleared, safe in hepatic impairment) and IV L-carnitine supplementation as the optimal strategy. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., specific lab abnormalities, EEG findings) to identify B as uniquely best without contradictions or underspecification. Alternatives are inferior: A and E continue valproate, risking ongoing toxicity; C uses phenytoin, which is hepatically metabolized and protein-bound, unsuitable in cirrhosis/hypoalbuminemia; D adds topiramate, potentially worsening hyperammonemia. Main medical accuracy issue(s): none; aligns with guidelines on valproate toxicity in liver disease, carnitine's role in mitigation, and levetiracetam's preference in hepatic impairment per neurology standards. Minimal fix: N/A, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include cirrhosis with portal hypertension, hyperammonemia (96 µmol/L), supratherapeutic free valproate despite therapeutic total level, low carnitine, EEG showing triphasic waves without epileptiform activity, and presentation of confusion/seizures suggestive of metabolic encephalopathy rather than primary epilepsy. These point to valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency, making discontinuation of valproate essential, with switch to levetiracetam (renally cleared, safe in hepatic impairment) and IV L-carnitine supplementation as the optimal strategy. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., specific lab abnormalities, EEG findings) to identify B as uniquely best without contradictions or underspecification. Alternatives are inferior: A and E continue valproate, risking ongoing toxicity; C uses phenytoin, which is hepatically metabolized and protein-bound, unsuitable in cirrhosis/hypoalbuminemia; D adds topiramate, potentially worsening hyperammonemia. Main medical accuracy issue(s): none; aligns with guidelines on valproate toxicity in liver disease, carnitine's role in mitigation, and levetiracetam's preference in hepatic impairment per neurology standards. Minimal fix: N/A, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]